Introduction
of DC BEAD™ on Key European Markets
Leuven, Belgium - March 31st, 2005
Terumo Europe NV, Interventional Systems, the affiliate of Terumo
Corporation Tokyo, Japan, announced today the introduction of a new
generation of
Microspheres, the DC Bead™, on key European Markets.
Since March
2003, Terumo Europe NV is the exclusive European distributor of Biocompatibles
International plc for Bead Block™. The introduction
of DC Bead™ enhances and develops the cooperation between Terumo
Europe and Biocompatibles International.
DC Bead™ will be introduced
by Terumo sales and Marketing teams in Germany, France, Italy, Switzerland,
Austria and Greece. Within 9
months, Terumo Europe aims to precise DC Bead™ utilisation, dosing,
clinical indication by working in close-cooperation with European interventional
radiologists.
DC Bead™ is a microsphere specifically designed and
prepared to be loaded with drug (doxorubicin in the present ongoing PRECISION
clinical
studies) in order to be injected through a catheter during an embolization
procedure. DC Bead™ is indicated for use in TACE (Trans-Arterial
Chemo-Embolization) of HCC (Hepatic Cell Carcinoma). Its concept is to
selectively reach the malignant tumor with more active drug inside the
tumour and with a very limited systemic effect in comparison with conventional
TACE procedure.
Thanks to its complete range of medical devices for embolotherapy
(guide-wire, micro-catheters and microspheres), Terumo Europe NV, Interventional
Systems,
wants to become a European leader on the Embolotherapy market.
About Terumo
TERUMO Europe NV is an affiliate of Terumo Corporation,
Tokyo, Japan, a premier global medical company with 2003 annual sales
in excess of
$2 billion. Terumo Corporation develops, manufactures, and markets a
wide range of medical products including cardiovascular systems, disposable
medical devices, therapeutic catheters, I.V. solutions, blood bags, diabetes
care systems, and medical electronic products in more than 150 countries.
Terumo global sales for year-end March 31st, 2004 were $2.0 billion,
of which $764 million was outside Japan.
Further information is available at www.terumo-europe.com
About Biocompatibles
International plc
Biocompatibles is a medical device company focused on the treatment of
cardiovascular disease, cancer and benign tumors. The Company’s
proprietary biomedical polymer systems provide medical devices with enhanced
biocompatibility and offer a platform for drug delivery. Further information
is available at www.biocompatibles.com
DC Bead ™
DC Bead™ is a precisely calibrated, compressible, visibility-tinted
microsphere made from polyvinyl alcohol (PVA), an established material
in embolization therapy, and licensed from BioCure Inc. (BioCure Inc
is a private medical device company, spun off from Novartis’ CibaVision
subsidiary, and headquartered in Norcross, Georgia USA). DC Bead™ has
CE mark approval for loading with doxorubicin and use I treatment of
malignant hypervascularized tumours. The concept of DC Bead™ microspheres
is to allow local, controlled and sustained delivery of a chemotherapy
agent in combination with embolization. Interventional radiologists use
embolization therapy to block blood flow to tumours or vascular malformations.
Contact:
Terumo Europe N.V.
Florence Pivert
European Communication Manager
Tel:
+32 16 40 02 49
E-mail: florence.pivert@terumo-europe.com
|